Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials

BACKGROUND: Dzherelo (Immunoxel) is one of the few approved immunomodulators that has been shown to produce positive treatment outcomes in patients with tuberculosis (TB). The aim of this review was to assess the effectiveness of Immunoxel used as adjunct therapy with conventional anti-TB therapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitenge, Marcel, Phiri, Bessie, Pheeha, Sara M., Ogunrombi, Modupe, Nyasulu, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157410/
https://www.ncbi.nlm.nih.gov/pubmed/34039420
http://dx.doi.org/10.1186/s13643-021-01698-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157410/
https://www.ncbi.nlm.nih.gov/pubmed/34039420
http://dx.doi.org/10.1186/s13643-021-01698-2

Ejemplares similares